

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) An injectable pharmaceutical composition containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid wherein substantially no sulfite is contained in the pharmaceutical composition.

2. (Canceled)

3. (Previously Presented) The injectable pharmaceutical composition according to claim 1, wherein glycyrrhizin is monoammonium glycyrrhizinate.

4. (Previously Presented) The injectable pharmaceutical composition according to claim 1, wherein cysteine is cysteine hydrochloride.

5-8. (Canceled)

9. (Currently Amended) The injectable pharmaceutical composition according to claim 1, wherein the concentration of cysteine in the pharmaceutical composition is more than 70% after the composition is stored at 60°C for 14 days is more than 70% of an initial concentration of cysteine in the pharmaceutical composition.

10. (Previously Presented) An injectable pharmaceutical composition containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate, 4 to 8 mg/mL of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid, wherein substantially no sulfite is contained in the pharmaceutical composition.

11. (Withdrawn) A method of treating hepatic diseases comprising: administering intravenously to a patient an injectable pharmaceutical composition containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid, wherein substantially no sulfite is contained in the pharmaceutical composition.

12. (Withdrawn) A method of treating allergy comprising: administering intravenously to a patient an injectable pharmaceutical composition containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid, wherein substantially no sulfite is contained in the pharmaceutical composition.

13. (Withdrawn) A method of treating hepatic diseases comprising: administering intravenously to a patient an injectable pharmaceutical composition containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate, 4 to 8 mg/mL of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid, wherein substantially no sulfite is contained in the pharmaceutical composition.

14. (Withdrawn) A method of treating allergy comprising: administering intravenously to a patient an injectable pharmaceutical composition containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate, 4 to 8 mg/mL of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid, wherein substantially no sulfite is contained in the pharmaceutical composition.